S&P 500   4,448.45 (-0.01%)
DOW   34,767.43 (+0.01%)
QQQ   370.90 (-0.56%)
AAPL   145.84 (-0.67%)
MSFT   297.38 (-0.73%)
FB   346.92 (+0.28%)
GOOGL   2,826.73 (+0.09%)
TSLA   764.01 (+1.38%)
AMZN   3,394.02 (-0.64%)
NVDA   218.71 (-2.72%)
BABA   145.67 (-3.65%)
NIO   35.61 (-1.11%)
CGC   14.06 (-3.43%)
GE   103.96 (+0.97%)
MU   74.23 (+0.26%)
AMD   104.92 (-1.16%)
T   27.29 (+0.37%)
F   13.88 (+1.24%)
ACB   6.03 (-1.95%)
DIS   175.50 (-0.43%)
PFE   44.16 (-0.07%)
BA   222.23 (+0.51%)
BAC   42.09 (+0.96%)
S&P 500   4,448.45 (-0.01%)
DOW   34,767.43 (+0.01%)
QQQ   370.90 (-0.56%)
AAPL   145.84 (-0.67%)
MSFT   297.38 (-0.73%)
FB   346.92 (+0.28%)
GOOGL   2,826.73 (+0.09%)
TSLA   764.01 (+1.38%)
AMZN   3,394.02 (-0.64%)
NVDA   218.71 (-2.72%)
BABA   145.67 (-3.65%)
NIO   35.61 (-1.11%)
CGC   14.06 (-3.43%)
GE   103.96 (+0.97%)
MU   74.23 (+0.26%)
AMD   104.92 (-1.16%)
T   27.29 (+0.37%)
F   13.88 (+1.24%)
ACB   6.03 (-1.95%)
DIS   175.50 (-0.43%)
PFE   44.16 (-0.07%)
BA   222.23 (+0.51%)
BAC   42.09 (+0.96%)
S&P 500   4,448.45 (-0.01%)
DOW   34,767.43 (+0.01%)
QQQ   370.90 (-0.56%)
AAPL   145.84 (-0.67%)
MSFT   297.38 (-0.73%)
FB   346.92 (+0.28%)
GOOGL   2,826.73 (+0.09%)
TSLA   764.01 (+1.38%)
AMZN   3,394.02 (-0.64%)
NVDA   218.71 (-2.72%)
BABA   145.67 (-3.65%)
NIO   35.61 (-1.11%)
CGC   14.06 (-3.43%)
GE   103.96 (+0.97%)
MU   74.23 (+0.26%)
AMD   104.92 (-1.16%)
T   27.29 (+0.37%)
F   13.88 (+1.24%)
ACB   6.03 (-1.95%)
DIS   175.50 (-0.43%)
PFE   44.16 (-0.07%)
BA   222.23 (+0.51%)
BAC   42.09 (+0.96%)
S&P 500   4,448.45 (-0.01%)
DOW   34,767.43 (+0.01%)
QQQ   370.90 (-0.56%)
AAPL   145.84 (-0.67%)
MSFT   297.38 (-0.73%)
FB   346.92 (+0.28%)
GOOGL   2,826.73 (+0.09%)
TSLA   764.01 (+1.38%)
AMZN   3,394.02 (-0.64%)
NVDA   218.71 (-2.72%)
BABA   145.67 (-3.65%)
NIO   35.61 (-1.11%)
CGC   14.06 (-3.43%)
GE   103.96 (+0.97%)
MU   74.23 (+0.26%)
AMD   104.92 (-1.16%)
T   27.29 (+0.37%)
F   13.88 (+1.24%)
ACB   6.03 (-1.95%)
DIS   175.50 (-0.43%)
PFE   44.16 (-0.07%)
BA   222.23 (+0.51%)
BAC   42.09 (+0.96%)
CVE:BCT

BriaCell Therapeutics Stock Forecast, Price & News

C$11.00
+0.59 (+5.67 %)
(As of 09/24/2021 10:59 AM ET)
Add
Compare
Today's Range
C$10.55
C$11.00
50-Day Range
C$5.52
C$10.55
52-Week Range
C$3.50
C$11.00
Volume20,062 shs
Average Volume13,126 shs
Market CapitalizationC$167.97 million
P/E Ratio9.05
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BCT News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.18 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BriaCell Therapeutics (CVE:BCT) Frequently Asked Questions

What stocks does MarketBeat like better than BriaCell Therapeutics?

Wall Street analysts have given BriaCell Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BriaCell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BriaCell Therapeutics' next earnings date?

BriaCell Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 29th 2021.
View our earnings forecast for BriaCell Therapeutics
.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (CVE:BCT) posted its quarterly earnings results on Tuesday, June, 29th. The company reported ($1.25) EPS for the quarter.
View BriaCell Therapeutics' earnings history
.

How has BriaCell Therapeutics' stock price been impacted by Coronavirus?

BriaCell Therapeutics' stock was trading at C$17.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BCT shares have decreased by 38.2% and is now trading at C$11.00.
View which stocks have been most impacted by COVID-19
.

Who are BriaCell Therapeutics' key executives?

BriaCell Therapeutics' management team includes the following people:
  • Dr. William V. Williams M.D., CEO, Pres & Director (Age 65, Pay $283.44k)
  • Dr. Charles Louis Wiseman M.D., FACP, Founder (Age 75, Pay $73.1k)
  • Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 48, Pay $52.5k)
  • Ms. Farrah Dean, Mang. of Corp. Devel.

What other stocks do shareholders of BriaCell Therapeutics own?

What is BriaCell Therapeutics' stock symbol?

BriaCell Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BCT."

How do I buy shares of BriaCell Therapeutics?

Shares of BCT and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BriaCell Therapeutics' stock price today?

One share of BCT stock can currently be purchased for approximately C$11.00.

How much money does BriaCell Therapeutics make?

BriaCell Therapeutics has a market capitalization of C$167.97 million.

How many employees does BriaCell Therapeutics have?

BriaCell Therapeutics employs 5 workers across the globe.

What is BriaCell Therapeutics' official website?

The official website for BriaCell Therapeutics is www.briacell.com.

Where are BriaCell Therapeutics' headquarters?

How can I contact BriaCell Therapeutics?

BriaCell Therapeutics' mailing address is Bellevue Centre, 235 15th St 3rd Floor, WEST VANCOUVER, BC V7T 2X1, Canada. The company can be reached via phone at +1-604-9211810.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.